Atlas Trials

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration

Clinical trial NCT01780935 · COMPLETED

Trial details

NCT number
NCT01780935
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2013-06-03
Primary completion
2015-07-09
Enrollment
671

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.